Racura Oncology Limited (ASX: RAC), a late clinical-stage biopharmaceutical company developing new small molecule-based approaches to cancer treatment focused on silencing MYC gene expression, today ...

The Safety Review Committee (SRC) has approved Racura Oncology’s (ASX:RAC) progression to 100 mg/m2 of RC220 in the HARNESS-1 ...

Racura Oncology Limited announced that the Safety Review Committee (SRC) for HARNESS-1 has cleared its lead oncology drug, RC220 to escalate to the next planned dose level of 100 mg/m2. HARNESS-1 (RAC ...

Last updated: October 11, 2026. More for You ...

Yields in the US and other advanced economies have climbed to multidecade highs, tightening financial conditions, amid higher ...

CONNEAUT — Council heard from two representatives of a company reviewing the possibility of bringing a data center to the ...

A new study shows that the macrophage enzyme MMP14 generates soluble semaphorin 4D, a signal that builds an immunosuppressive tumor microenvironment and excludes anti-cancer T cells.

Researchers have developed a Matrigel-free, aloe vera-containing bioink for 3D-printing bone organoids that recruit and polarize macrophages toward a pro-regenerative state, accelerating repair of ...

Proof of concept demonstrated for first-in-class oral therapy, addressing multiple aspects of atopic dermatitis pathology and with the potential ...

A Kern County oilman briefed two Cabinet secretaries on a plan to store sunlight as heat in old California oil fields for ...

Sitryx Therapeutics announced positive topline results from a Phase 1b trial of SYX-5219, a first-in-class oral pyruvate ...

SALT LAKE CITY, Oct. 7, 2026 /PRNewswire/ -- Lipocine Inc. (NASDAQ: LPCN), a specialty pharmaceutical company focused on the development of novel oral therapeutics, today announced that, through ...